Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Mammary Cancer
Interventions: DRUG: Pertuzumab and trastuzumab FDC subcutaneous|DRUG: Paclitaxel|DRUG: TDM1|DRUG: Endocrine therapy|PROCEDURE: Omission surgery
Sponsor: David Garcia Cinca
Collaborators: Fundacion Clinic per a la Recerca Biomédica